Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Summary

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Conditions

• Metastatic Colorectal Cancer

Interventions

DRUG

Alectinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.

DRUG

Cetuximab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Crizotinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Dasatinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Everolimus

Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

DRUG

Encorafenib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Gemcitabine

Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

DRUG

Idelalisib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Larotrectinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Methotrexate

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Palbociclib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Panobinostat

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Pembrolizumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Petrozumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Trastuzumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Talazoparib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUG

Venetoclax

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

Sponsors & Collaborators

• Oslo University Hospital

  lead OTHER

Principal Investigators

• Tormod K Guren, MDPhD · Oslo University Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-09-27

Primary Completion

2038-12-31

Completion

2040-12-31

Countries

• Norway

Study Locations